By the end of the decade, projections suggest that market growth in psychedelic therapies could approach a $20 billion mark, with approximately $15 billion attributed solely to Transcranial Magnetic Stimulation (TMS). When comparing costs over five years between traditional medication and TMS, the efficacy and cost-benefit of TMS become evident, making it a compelling option […]

By the end of the decade, projections suggest that market growth in psychedelic therapies could approach a $20 billion mark, with approximately $15 billion attributed solely to Transcranial Magnetic Stimulation (TMS). When comparing costs over five years between traditional medication and TMS, the efficacy and cost-benefit of TMS become evident, making it a compelling option that could revolutionize mental health care in the coming years.